杜普伊特伦挛缩症的全球市场

预计到 2030 年，全球杜普伊特伦挛缩症市场规模将达到 107 亿美元

2024年，全球杜普伊特伦挛缩症市场规模估计为88亿美元，预计2030年将达到107亿美元，2024年至2030年的复合年增长率为3.3%。本报告分析的I型杜普伊特伦挛缩症细分市场预计复合年增长率为3.8%，到分析期结束时市场规模将达到63亿美元。 II型杜普伊特伦挛缩症细分市场预计在分析期间内复合年增长率为2.6%。

美国市场规模估计为 24 亿美元，中国市场预计复合年增长率为 6.3%

美国杜普伊特伦挛缩症市场规模预计在2024年达到24亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到21亿美元，在2024-2030年的分析期间内，复合年增长率为6.3%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为1.3%和2.6%。在欧洲，预计德国市场的复合年增长率为1.9%。

全球杜普伊特伦挛缩症市场—主要趋势与驱动因素摘要

为什么杜普伊特伦挛缩症比以往更受临床关注？

杜普伊特伦挛缩症是一种慢性掌筋膜纤维化疾病，已从一种小众的外科疾病演变为一种广受认可的疾病，其治疗兴趣也日益增长。杜普伊特伦挛缩症曾被认为是一种相对局部性的疾病，仅影响老年白人男性，但近年来，随着监测和诊断技术的进步，该疾病在不同人群和地理区域广泛流行。随着越来越多的患者在出现严重挛缩之前就出现早期症状，例如腱索结节和增厚，医生越来越重视早期发现和非侵入性干预。杜普伊特伦挛缩症如今已不再仅被认为是一种手部畸形，而是一种系统性纤维增生性疾病，其可能与其他疾病（例如佩罗尼氏症和肩周炎）共用的病理学途径。这些关联促使人们采取更全面的治疗和诊断方法。此疾病的潜伏性进展以及手指挛缩（限制基本手部功能）带来的社会心理影响，也促使医疗保健提供者制定长期管理策略，而非被动采取手术应对措施。因此，临床指南和患者期望都在不断发展，以支持及时治疗、预防性护理和改善生活质量，这为市场成长和创新创造了肥沃的土壤。

微创治疗选择如何改变治疗格局？

传统的杜普伊特伦挛缩症治疗严重依赖开放性手术切除术，这通常与较长的恢復期、手术风险和相对较高的復发率有关。然而，微创治疗的日益普及和临床检验正在迅速改变治疗模式。酵素注射，特别是胶原蛋白酶溶组织梭菌 (CCH)，已成为手术的突破性替代方法，可有效阻断脊髓损伤，同时显着缩短恢復时间并降低手术成本。针刺肌腱切除手术是另一种微创手术，由于其简单、快速见效和门诊环境，正在专家中越来越受欢迎。这些方法对于早期或中期疾病病例尤其有吸引力，越来越多的临床研究显示其良好的安全性和有效性结果。此外，研究人员正在探索针对纤维母细胞活性和抑制纤维母细胞增殖的新型药物，这可能会改变疾病的自然史。非手术治疗方案的增多，正在将治疗重心从整形外科专家转移到更广泛的医学专科，包括皮肤科医生、风湿症医师和全科医生，从而催生出一个不断扩大的市场。这些替代疗法的出现不仅改变了患者护理，也重新定义了医疗保健体系中针对慢性肌肉骨骼疾病的策略。

在这个利基但不断扩大的行业中，区域差异和市场区隔的驱动因素是什么？

儘管在许多地区杜普伊特伦挛缩症被认为是罕见疾病，但它表现出明显的地理和种族差异，这影响了市场区隔和治疗需求。虽然这种疾病在北欧人中最为常见，尤其是维京血统的人，但北美和亚洲部分地区的诊断率正在上升，这表明全球负担未被充分认识。饮酒、吸烟、糖尿病盛行率和职业压力等生活方式因素被视为风险因素，使其成为区域医疗保健宣传活动的重点。德国、英国和美国等人口老化和医疗保健系统发达的国家对具有成本效益的门诊和后续护理有强烈的需求。相反，由于认识的提高、医疗保健资金的增加以及透过医学会议和远端医疗在全球传播最佳实践，新兴市场正在逐渐赶上。随着从早期疗育套件到治疗后復健辅助设备等新设备和治疗工具的开发，以针对疾病的特定阶段，市场区隔也变得更加明显。此外，区域付款人偏好和覆盖政策影响各种治疗方法的可近性和可负担性，使得区域政策框架成为市场策略规划的关键组成部分。

杜普伊特伦挛缩症治疗市场的发展动力是什么？

杜普伊特伦挛缩症治疗市场的成长受到多种因素的驱动，这些因素与治疗方法创新、临床实践的变革以及患者行为的演变有关。其中一个关键驱动因素是胶原蛋白酶注射和针刺肌腱切断术等微创技术的日益普及，这激发了先前不愿接受手术的患者对治疗的兴趣。更先进的诊断工具和医生意识的提升使得早期早期疗育，并相应增加了门诊治疗的需求。医学影像和数位健康平台的技术进步使得诊断、治疗方案和长期监测更加精准，从而降低了復发率并提高了患者满意度。此外，全球人口老化，尤其是在已开发国家，正在加剧高风险族群的扩张，而糖尿病和吸烟相关疾病等合併症则进一步推高了盛行率。新兴市场医疗基础设施的改善和可支配收入的提高也正在释放先前尚未开发的市场，尤其是在采用西方治疗模式的地区。在消费者方面，人们对手部活动能力、职场效率和美观度的日益关注，促使人们寻求早期治疗。这些动态共同推动了杜普伊特伦挛缩症治疗市场的强劲成长，并为创新和可近性开闢了新的途径。

部分

疾病类型（I型、II型、III型）；类型（诊断、治疗）；最终使用者（医院、诊所、学术/研究机构等）

受访公司范例

• Actiza Pharmaceutical Pvt. Ltd.
• AstraZeneca PLC
• Bayer AG
• BioSpecifics Technologies Corp.
• Bristol-Myers Squibb Company
• Endo International plc
• Fortress Biotech, Inc.
• Fresenius Kabi AG
• GlaxoSmithKline plc（GSK）
• Hikma Pharmaceuticals PLC
• Johnson & Johnson
• LEO Pharma A/S
• Merck & Co., Inc.
• Nantong Jinghua Pharmaceutical Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Spear Pharmaceuticals
• 180 Life Sciences Corp.
• West-Ward Pharmaceuticals
• Xian Janssen Pharmaceutical Ltd.

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地以及进出口情况（成品和原始OEM）预测其竞争地位的变化。这种复杂多变的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Dupuytren's Disease Market to Reach US$10.7 Billion by 2030

The global market for Dupuytren's Disease estimated at US$8.8 Billion in the year 2024, is expected to reach US$10.7 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Type I, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Type II segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 6.3% CAGR

The Dupuytren's Disease market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Dupuytren's Disease Market - Key Trends & Drivers Summarized

Why Is Dupuytren’s Disease Attracting Greater Clinical Attention Than Ever Before?

Dupuytren’s disease, a chronic fibrosing condition of the palmar fascia, has evolved from being a niche surgical concern to a widely acknowledged medical disorder with increasing therapeutic interest. Once considered a relatively localized issue among older Caucasian males, recent research and diagnostic advances have revealed its broader prevalence across different demographics and geographic regions. As more patients present with earlier-stage symptoms such as nodules and thickened cords before severe contracture sets in, physicians are focusing more on early detection and non-invasive intervention. Dupuytren’s disease is now recognized not merely as a hand deformity but as a systemic fibroproliferative disorder that may share pathophysiological pathways with other conditions such as Peyronie’s disease and frozen shoulder. These associations are encouraging a more holistic approach to treatment and diagnosis. The disease’s insidious progression and the psychosocial impact of finger contracture-limiting basic hand function-are also prompting healthcare providers to develop long-term management strategies, rather than reactive surgical responses. Consequently, both clinical guidelines and patient expectations are evolving to support timely therapeutic engagement, preventive care, and improved quality of life, creating fertile ground for market growth and innovation.

How Are Minimally Invasive Options Reshaping the Treatment Landscape?

Traditional treatment of Dupuytren’s disease was heavily reliant on open surgical fasciectomy, a procedure often associated with long recovery periods, surgical risks, and relatively high recurrence rates. However, the therapeutic paradigm is shifting rapidly due to the growing popularity and clinical validation of minimally invasive treatments. Enzymatic injections, especially collagenase clostridium histolyticum (CCH), have emerged as a revolutionary non-surgical option, offering effective cord disruption with significantly reduced recovery times and lower procedural costs. Needle aponeurotomy, another minimally invasive technique, is gaining momentum among specialists for its simplicity, immediate results, and the ability to be performed in outpatient settings. These approaches are becoming particularly appealing for early-stage or moderate disease cases and are being supported by an increasing number of clinical studies showcasing favorable safety and efficacy outcomes. Additionally, researchers are exploring novel agents that target fibroblast activity and reduce myofibroblast proliferation, potentially altering the natural course of the disease. This rise in non-surgical options is also shifting treatment from orthopedic specialists to broader segments of the medical community, including dermatologists, rheumatologists, and general practitioners, thereby expanding market reach. The availability of these alternative treatments is not only transforming patient care but also redefining healthcare system strategies for chronic musculoskeletal conditions.

What Drives Regional Variability and Market Segmentation in This Niche Yet Expanding Field?

Despite being considered a rare condition in many regions, Dupuytren’s disease shows notable geographic and ethnic variation that is influencing market segmentation and treatment demand. The condition remains most prevalent in Northern European populations, particularly among those with Viking ancestry, but increasing diagnosis rates in North America and parts of Asia are suggesting an under-recognized global burden. Lifestyle factors such as alcohol consumption, smoking, diabetes prevalence, and occupational strain appear to be contributory risk factors and are becoming focal points for regional healthcare campaigns. In countries with aging populations and advanced healthcare systems, such as Germany, the UK, and the US, there is significant demand for cost-effective outpatient treatments and follow-up care options. Conversely, emerging markets are gradually catching up due to better awareness, increased healthcare funding, and the global dissemination of best practices through medical conferences and telemedicine. Market segmentation is also becoming more pronounced as new devices and therapeutic tools are developed for specific stages of the disease, from early intervention kits to specialized post-treatment rehabilitation aids. Additionally, payer preferences and insurance coverage policies across regions are influencing both the accessibility and affordability of different treatment modalities, making regional policy frameworks a key component in market strategy planning.

What Is Fueling the Rising Momentum in the Dupuytren’s Disease Treatment Market?

The growth in the Dupuytren’s disease treatment market is driven by several factors related to therapeutic innovation, shifting clinical practices, and evolving patient behavior. One of the primary drivers is the expanding adoption of minimally invasive techniques such as collagenase injections and needle aponeurotomy, which are increasing treatment uptake among patients who previously avoided surgery. The broader recognition of early-stage disease, aided by better diagnostic tools and increased physician awareness, is leading to earlier intervention and a corresponding rise in demand for outpatient therapies. Technological advancements in medical imaging and digital health platforms are enabling more precise diagnosis, treatment planning, and long-term monitoring, which in turn are reducing recurrence rates and improving patient satisfaction. Additionally, an aging global population, particularly in developed nations, is contributing to a larger at-risk cohort, while comorbidities like diabetes and smoking-related disorders are further inflating incidence rates. Healthcare infrastructure improvements and rising disposable incomes in developing regions are also unlocking previously untapped markets, especially where Western treatment models are being adopted. On the consumer side, growing awareness around hand mobility, workplace productivity, and aesthetic concerns is encouraging individuals to seek earlier treatment, while payer systems in many countries are expanding coverage for non-surgical therapies. Collectively, these dynamics are driving robust growth in the Dupuytren’s disease treatment market and opening new avenues for innovation and accessibility.

SCOPE OF STUDY:

The report analyzes the Dupuytren's Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Type I, Type II, Type III); Type (Diagnosis, Treatment); End-Use (Hospitals, Clinics, Academic & Research Institute, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Actiza Pharmaceutical Pvt. Ltd.
• AstraZeneca PLC
• Bayer AG
• BioSpecifics Technologies Corp.
• Bristol-Myers Squibb Company
• Endo International plc
• Fortress Biotech, Inc.
• Fresenius Kabi AG
• GlaxoSmithKline plc (GSK)
• Hikma Pharmaceuticals PLC
• Johnson & Johnson
• LEO Pharma A/S
• Merck & Co., Inc.
• Nantong Jinghua Pharmaceutical Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Spear Pharmaceuticals
• 180 Life Sciences Corp.
• West-Ward Pharmaceuticals
• Xian Janssen Pharmaceutical Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Dupuytren's Disease - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Awareness and Early Diagnosis Throws the Spotlight on Dupuytren's Disease as a Manageable Hand Disorder
  • Aging Population and Increased Incidence Among Older Adults Propel Demand for Effective Treatment Options
  • Minimally Invasive Therapies and Non-Surgical Interventions Spur Growth in Patient-Centric Treatment Approaches
  • Innovation in Collagenase Clostridium Histolyticum Injections Strengthens the Business Case for Outpatient Procedures
  • Growing Focus on Hand Function and Quality of Life Accelerates Adoption of Early-Stage, Less Invasive Therapies
  • Reintroduction of Collagenase-Based Therapies in Key Markets Expands the Addressable Market for Recurrence-Prone Cases
  • Surgical Advancements and Post-Operative Rehabilitation Solutions Drive Demand in Advanced and Refractory Disease Stages
  • Development of Combination Therapies and Adjunctive Treatments Generates Opportunities for Long-Term Disease Management
  • Rising Use of Ultrasound and Imaging-Guided Interventions Enhances Precision in Minimally Invasive Treatment Delivery
  • Globalization of Specialty Care and Medical Tourism Opens New Markets for Advanced Dupuytren's Disease Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Dupuytren's Disease Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Dupuytren's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Type I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Type I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Type I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Type II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Type II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Type II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Type III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Type III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Type III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Academic & Research Institute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Academic & Research Institute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Academic & Research Institute by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• JAPAN
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• CHINA
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• EUROPE
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Dupuytren's Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• FRANCE
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• GERMANY
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Dupuytren's Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• INDIA
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Dupuytren's Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Dupuytren's Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Dupuytren's Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030
• AFRICA
  • Dupuytren's Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Dupuytren's Disease by Disease Type - Type I, Type II and Type III - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Dupuytren's Disease by Disease Type - Type I, Type II and Type III Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Dupuytren's Disease by Disease Type - Percentage Breakdown of Value Sales for Type I, Type II and Type III for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Dupuytren's Disease by Type - Diagnosis and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Dupuytren's Disease by Type - Diagnosis and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Dupuytren's Disease by Type - Percentage Breakdown of Value Sales for Diagnosis and Treatment for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Dupuytren's Disease by End-Use - Hospitals, Clinics, Academic & Research Institute and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Dupuytren's Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Academic & Research Institute and Others for the Years 2015, 2025 & 2030

IV. COMPETITION